Jude Pediatric Cancer Genome Project (PCGP) using next-generation sequencing showed that besides amplification of MYC, MYCN, CCND2/CYCLIN D2, CDK6, and GLI2 and mutations in β-CATENIN, PTCH1, SUFU, and TP53, mutations in epigenetic regulators account for the majority of genetic perturbations in G3 and G4 MBs (Table 2) [9, 12, 13]. Here, MYC is linked to Mobius syndrome.